干扰素治疗慢性乙型肝炎发生HBeAg血清学转换的预测因素

Predictors of HBeAg Serological Conversion in Interferon Treatment of Chronic Hepatitis B

慢性乙型肝炎(CHB)患者在干扰素抗病毒治疗过程中发生HBeAg血清学转换是较理想的目标。干扰素治疗一年仅有约1/3的患者发生HBeAg的血清转换,对血清转换的预测很重要。研究发现,影响CHB患者在干扰素治疗过程中发生HBeAg血清学转换的因素有HBV-DNA水平、HBeAg定量、HBsAg定量、血清丙氨酸氨基转移酶水平、病毒基因型、病毒变异和肝组织的炎症分级等方面。研究相关的预测因素,以利于对干扰素治疗患者的选择和评估。

HBeAg serological conversion occurrence in chronic hepatitis B （COB）interferon antiviral treatmentis an ideal goal. However,its efficacy is limited in about 1/3 of patients after one year of interferon treatment. So it is very important to identify potential predictors of durable off-treatment HBeAg seroconver- sion. The factors of HBeAg serological conversion in interferon treatment of chronic hepatitis B are HBV- DlqA, HBeAg, HBsAg, ALT quantitative level, viral genotype, viral mutation and liver tissue inflammatory grading etc. Here is to summarize the relevant predicting factors in order to select and evaluate patient in interferon treatment.